ABSTRACT
RESUMEN Introducción y objetivos: El sarcoma mieloide puede ser la primera manifestación de la leucemia mieloide aguda (LMA), presentarse simultáneamente o constituir una forma de recaída. Material y métodos: Presentamos el caso de una paciente con sarcoma mieloide uterino, como forma de recaída de LMA. Resultados: El diagnóstico se basa en los hallazgos histopatológicos, la inmunohistoquímica y el inmunofenotipo. El tratamiento y el pronóstico son similares a LMA. Conclusión: La afectación uterina por leucemia mieloide extramedular es rara pero debe tenerse en cuenta en el diagnostico diferencial de una masa uterina en aquellas pacientes con antecedentes de LMA.
ABSTRACT Introduction and objectives: Myeloid Sarcoma can present as a first MLA sign, concurrently with or at relapse form. Materials and methods: We present the case of a patient with uterine myeloid sarcoma, as a form of relapse of MLA. Results: The diagnostic is based on the histopathology findings along with immunohistochemistry and immunophenotyping. Conclusion: Uterine involvement due to extramedullary myeloid leukemia is rare but it should be taken into account in the differential diagnosis of a uterine mass in those patients with a history of MLA.
Subject(s)
Humans , Female , Aged , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/therapy , Sarcoma, Myeloid/diagnostic imaging , Thrombosis , Immunohistochemistry , Magnetic Resonance Spectroscopy , Leukemia, Myeloid, Acute/pathologySubject(s)
Carcinoma, Papillary/secondary , Liver Neoplasms/secondary , Ovarian Neoplasms/pathology , Peritoneal Neoplasms/secondary , Struma Ovarii/secondary , Antineoplastic Agents/therapeutic use , Carcinoma, Papillary/diagnosis , Carcinoma, Papillary/drug therapy , Cell Differentiation , Cisplatin/administration & dosage , Combined Modality Therapy , Doxorubicin/administration & dosage , Fatal Outcome , Female , Humans , Hysterectomy , Iodine Radioisotopes/therapeutic use , Liver Neoplasms/drug therapy , Middle Aged , Ovarian Neoplasms/surgery , Peritoneal Neoplasms/drug therapy , Struma Ovarii/drug therapy , Struma Ovarii/surgery , ThyroidectomyABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Struma Ovarii/diagnosis , Struma Ovarii/surgery , Neoplasm Metastasis/diagnosis , Laparotomy/methods , Thyroidectomy/methods , Thyroxine/therapeutic use , CA-125 Antigen/analysis , Biomarkers, Tumor/analysis , Laparoscopy/methods , Iodine Radioisotopes/therapeutic useABSTRACT
La incidencia de neoplasia de vulva ronda el 1-2 por 100 000 mujeres con predominancia en rangos etarios de diagnóstico entre los 65 -75 años. Este tipo de patología oncológica se aborda con técnicas quirúrgicas resumidas en vulvectomía simple o vulvectomía con linfadenectomía unilateral o bilateral según estadiaje de afectación cutánea. La morbilidad de este proceso quirúrgico se agrupa principalmente en la humedad cutánea, dehiscencia e infección. La utilización de Nobecutan® en aerosol como apósito plástico barrera disminuye la comorbilidad quirúrgica cutánea (AU)
The incidence of neoplasia of vulva round 1-2 per 100 000 women with predominance in ranges age of diagnosis between 65-75 years. This type of cancer pathology is tackled with surgical techniques summarized in simple vulvectomy or vulvectomy with unilateral or bilateral lymphadenectomy according to staging of cutaneous involvement. The morbidity of this surgical process is mainly grouped in skin moisture, dehiscence and infection. The use of Nobecutan® as a plastic dressing aerosol barrier reduces cutaneous surgical comorbidity (AU)
Subject(s)
Humans , Female , Wound Closure Techniques/instrumentation , Vulvar Neoplasms/surgery , Bandages , Surgical Wound Infection/prevention & control , Wound Healing/physiology , Lymph Node Excision , Postoperative Complications/prevention & controlABSTRACT
The incidence of neoplasia of vulva round 1-2 per 100,000 women with predominance in ranges age of diagnosis between 65-75years. This type of cancer pathology is tackled with surgical techniques summarized in simple vulvectomy or vulvectomy with unilateral or bilateral lymphadenectomy according to staging of cutaneous involvement. The morbidity of this surgical process is mainly grouped in skin moisture, dehiscence and infection. The use of Nobecutan® as a plastic dressing aerosol barrier reduces cutaneous surgical comorbidity.
